https://www.selleckchem.com/products/AG14361.html
6m vs.11.0m, p=0.04). Patients with brain metastasis had a significantly higher risk of death (HR 5.90; 95% CI 2.01-17.30; P=0.001). Patients whose ECOG was 0 and 1 had a significantly lower risk of death (HR 0.36; 95% CI 0.14-0.91; P=0.031). Anlotinib plus camrelizumab had shown promising efficacy and manageable toxicity as a second-line or later-line treatment for NSCLCs, especially in the 12mg cohorts. Large-scale phase III clinical trials are needed to further explore the rational combination models and biomarkers. Anlotinib plus ca